摘要
目的:系统评价疏血通联合依达拉奉治疗急性脑梗死(ACI)的安全性和有效性。方法:检索中国生物医学文献数据库(1978～2009)、中文科技期刊全文数据库(1979～2009)纳入疏血通联合依达拉奉治疗ACI的随机对照试验(RCT),手工检索其他的相关文献,对纳入研究进行方法学质量评价,并采用RevMan 5.0.0软件对其进行Meta分析。结果:共纳入11个RCT,967例患者;疏血通联合依达拉奉对比常规方法治疗ACI患者,痊愈率和总有效率联合组优于常规组,分别为[RR1.75,95%CI(1.30,2.35)]和[RR1.38,95%CI(1.22,1.55)]。疏血通联合依达拉奉对比单用依达拉奉治疗ACI的基本痊愈率和总有效率,联合组均优于单用组,且差异有统计学意义,其RR和95%CI分别为[:RR1.43,95%CI(1.03,1.97])和[RR1.16,95%CI(1.06,1.27)]。结论:疏血通联合依达拉奉能明显提高ACI患者治疗后的总有效率和痊愈率,疗效显著,未见明显不良反应。
OBJECTIVE：To evaluate effectiveness and safety of shuxuetong combined with edaravone for acute cerebral infarction（ACI.） METHODS：Randomized controlled trails（RCT）on shuxuetong combined with edaravone for ACI were retrieved from CBM WEB（1978～2009）and CNKI（1979～2009）,while other relative researches were performed by hand.Methodological quality evaluation of included study was conducted.RevMan 5.0.0 software was used for metaanalysis.RESULTS：11 RCT and 967 patients were included.The cure rate and total response rate of combination group were better than those of routine group;in combination group the RR and 95%CI were [RR1.75,95%CI（1.30,2.35）] and [RR1.38,95%CI（1.22,1.55）].The basic cure rate and total response rate of combination group were better than those of single group;in single group the RR and 95%CI were [RR1.43,95%CI（1.03,1.97）] and [RR1.16,95%CI（1.06,1.27）].CONCLUSION：Shuxuetong combined with edaravone improve cure rate and total effective rate of ACI therapy.It is effective in the treatment of ACI without obvious ADR and worthy of spreading.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第36期3426-3429,共4页
China Pharmacy
关键词
依达拉奉
疏血通
急性脑梗死
系统评价
Edaravone
Shuxuetong
Acute cerebral infarction
Systematic review
